

## HR 597

Pandemic Treatment Access and Affordability Act of 2021

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Jan 28, 2021

**Current Status:** Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

**Latest Action:** Referred to the Subcommittee on Courts, Intellectual Property, and the Internet. (Mar 22, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/597>

### Sponsor

---

**Name:** Rep. Schakowsky, Janice D. [D-IL-9]

**Party:** Democratic • **State:** IL • **Chamber:** House

## Cosponsors (26 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Jan 28, 2021
Rep. Bishop, Sanford D., Jr. [D-GA-2]	D · GA		Jan 28, 2021
Rep. Chu, Judy [D-CA-27]	D · CA		Jan 28, 2021
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		Jan 28, 2021
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Jan 28, 2021
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Jan 28, 2021
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Jan 28, 2021
Rep. Jayapal, Pramila [D-WA-7]	D · WA		Jan 28, 2021
Rep. Khanna, Ro [D-CA-17]	D · CA		Jan 28, 2021
Rep. McCollum, Betty [D-MN-4]	D · MN		Jan 28, 2021
Rep. Pingree, Chellie [D-ME-1]	D · ME		Jan 28, 2021
Rep. Pocan, Mark [D-WI-2]	D · WI		Jan 28, 2021
Rep. Raskin, Jamie [D-MD-8]	D · MD		Jan 28, 2021
Rep. Welch, Peter [D-VT-At Large]	D · VT		Jan 28, 2021
Del. San Nicolas, Michael F. Q. [D-GU-At Large]	D · GU		Feb 22, 2021
Rep. Carson, Andre [D-IN-7]	D · IN		Feb 22, 2021
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		Feb 22, 2021
Rep. Evans, Dwight [D-PA-3]	D · PA		Feb 22, 2021
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Feb 22, 2021
Rep. Lawson, Al, Jr. [D-FL-5]	D · FL		Feb 23, 2021
Rep. Scanlon, Mary Gay [D-PA-5]	D · PA		Feb 23, 2021
Rep. Titus, Dina [D-NV-1]	D · NV		Feb 23, 2021
Rep. Cohen, Steve [D-TN-9]	D · TN		Mar 26, 2021
Rep. Hayes, Jahana [D-CT-5]	D · CT		Mar 26, 2021
Rep. Price, David E. [D-NC-4]	D · NC		May 4, 2021
Rep. Thompson, Bennie G. [D-MS-2]	D · MS		May 28, 2021

## Committee Activity

Committee	Chamber	Activity	Date
Armed Services Committee	House	Referred To	Jan 28, 2021
Energy and Commerce Committee	House	Referred to	Feb 2, 2021
Judiciary Committee	House	Referred to	Mar 22, 2021
Science, Space, and Technology Committee	House	Referred To	Jan 28, 2021

## Subjects & Policy Tags

### Policy Area:

Health

### Related Bills

*No related bills are listed.*

## **Pandemic Treatment Access and Affordability Act of 2021**

This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.

With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill.

The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access.

If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.

### **Actions Timeline**

---

- **Mar 22, 2021:** Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
- **Feb 2, 2021:** Referred to the Subcommittee on Health.
- **Jan 28, 2021:** Introduced in House
- **Jan 28, 2021:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.